Home > Research Institute > Available Trials > Phase 3 Study of Adjuvant Endocrine Therapy vs. Imlunestrant
Phase 3 Study of Adjuvant Endocrine Therapy vs. Imlunestrant
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Disease Types: Breast
Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
For More information: